LTTL treatment lowered IL-17A overexpression while the intrathecal administration of IL-17A antibodies mitigated bone-cancer–evoked nociception in a dose-dependent manner, revealing that astrocyte-produced IL-17A might endorse cancer-related pain. This evidence concerns the gene IL17A and bone cancer.